{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T18:10:18Z","timestamp":1789150218456,"version":"build-2803163510"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Real-world evidence on therapeutic plasma exchange (TPE) from low- and middle-income countries remains limited. Egyptian data across multiple organ systems are scarce. This study aimed to evaluate the indications, safety, efficacy, and predictors of outcomes in patients undergoing TPE at a tertiary center in Egypt over 7 years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods and Findings<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study included 221 consecutive patients who underwent TPE (2016\u20132022) at Zagazig University Hospitals, Egypt. Patients were stratified into renal, neurologic, hematologic, and metabolic groups. Primary outcomes were clinical response and all-cause mortality. Multivariate logistic regression, Cox proportional hazards models, and Kaplan\u2013Meier survival analysis were performed. Among 221 patients (57.9% male; mean age 36.0 years), the most frequent indications were Guillain\u2013Barr\u00e9 syndrome, thrombotic thrombocytopenic purpura, and myasthenia gravis crisis. ASFA category I indications constituted 77.8% of procedures, with response rates decreasing significantly across categories (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03). Overall response rate was 77.9% (complete remission in 93.0% of responders), with mortality 14.5%. Response rates exceeded 85% in autoimmune hemolytic anemia, hyperviscosity syndrome, and TTP. Neurologic indications achieved 81.6% response; renal indications showed lower response (73.2%) and highest mortality (21.3%). Adverse events occurred in 37.2% of patients, all mild-to-moderate with no session terminations. Independent mortality predictors included mechanical ventilation, creatinine &gt;2.5 mg\/dL, renal indication, hemoglobin &lt;8 g\/dL, while ASFA category I was protective (all aORs 2.67\u20135.22). In exploratory analyses, PLASMIC score \u22656 and time to TPE\u2009\u2264\u20092 days were associated with complete remission in TTP, while Hughes score \u22654 and time to TPE\u2009&gt;\u20097 days were associated with poor functional outcome in GBS. These findings require external validation before clinical application. Diffuse alveolar hemorrhage (n\u2009=\u20099) demonstrated 100% mortality despite intervention, whereas SLE patients (n\u2009=\u200923) had 52.2% mortality, with 47.8% achieving complete remission or clinical improvement. A three-tier risk model stratified patients into high, intermediate, and low mortality risk groups. Independent predictors of clinical response included neurologic, hematologic, and metabolic indications compared to renal, ASFA category I, and \u22655 TPE sessions, while hemoglobin &lt;8 g\/dL and creatinine &gt;2.5 mg\/dL predicted poorer response.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This single-center Egyptian TPE cohort demonstrates high efficacy and safety when aligned with ASFA guidelines. Neurologic and hematologic indications achieve optimal outcomes; renal indications and critical illness markers predict poorer prognosis. The PLASMIC score, treatment urgency in TTP and GBS, and the proposed three-tier model represent exploratory findings that, if prospectively validated, could become actionable prognostic tools. These findings suggest that evidence-based TPE expansion in resource-limited settings may be feasible, though multicenter validation is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0358069","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:41:16Z","timestamp":1789148476000},"page":"e0358069","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic plasma exchange across multiple organ systems in an Egyptian tertiary center: A seven-year real-world cohort study"],"prefix":"10.1371","volume":"21","author":[{"given":"Mohamed Ahmed","family":"El Maghawry","sequence":"first","affiliation":[{"name":"Zagazig University","place":["Zagazig, Egypt"],"department":["Internal Medicine Department, Faculty of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reham Abd","family":"Elkhalek","sequence":"additional","affiliation":[{"name":"Zagazig University","place":["Zagazig, Egypt"],"department":["Rheumatology and Rehabilitation Department, Faculty of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Altaher","family":"Taha","sequence":"additional","affiliation":[{"name":"Zagazig University","place":["Zagazig, Egypt"],"department":["Internal Medicine Department, Faculty of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8191-0035","authenticated-orcid":true,"given":"Amira A. A.","family":"Othman","sequence":"additional","affiliation":[{"name":"Suez University","place":["Suez, Egypt"],"department":["Internal Medicine Department, Faculty of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliaa Mohamed Abd El Khalik","family":"Ahmed","sequence":"additional","affiliation":[{"name":"Zagazig University","place":["Zagazig, Egypt"],"department":["Neurology Department, Faculty of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina A.","family":"Abdelhady","sequence":"additional","affiliation":[{"name":"Zagazig University","place":["Zagazig, Egypt"],"department":["Clinical Pathology Department, Faculty of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma M. Attia","family":"Elsayed","sequence":"additional","affiliation":[{"name":"Zagazig University","place":["Zagazig, Egypt"],"department":["Internal Medicine Department, Faculty of Medicine"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"issue":"1","key":"pone.0358069.ref001","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/asheducation.V2012.1.7.3797920","article-title":"Plasma exchange: concepts, mechanisms, and an overview of the American Society for Apheresis guidelines","volume":"2012","author":"JL Winters","year":"2012","journal-title":"Hematology"},{"issue":"1","key":"pone.0358069.ref002","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jca.21257","article-title":"Therapeutic plasma exchange: a technical and operational review","volume":"28","author":"AA Kaplan","year":"2013","journal-title":"J Clin Apher"},{"issue":"7","key":"pone.0358069.ref003","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3390\/biom15071000","article-title":"Therapeutic Plasma Exchange: Current and Emerging Applications to Mitigate Cellular Signaling in Disease","volume":"15","author":"RMIK Rony","year":"2025","journal-title":"Biomolecules"},{"issue":"2","key":"pone.0358069.ref004","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice - Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue","volume":"38","author":"L Connelly-Smith","year":"2023","journal-title":"J Clin Apher"},{"issue":"1","key":"pone.0358069.ref005","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12882-025-03970-2","article-title":"Indications and complications associated with centrifuge-based therapeutic plasma exchange - a retrospective review","volume":"26","author":"D Warner","year":"2025","journal-title":"BMC Nephrol"},{"key":"pone.0358069.ref006","doi-asserted-by":"crossref","first-page":"04214","DOI":"10.7189\/jogh.15.04214","article-title":"Therapeutic plasma exchange in critically ill patients in low-income and lower-middle-income countries: medical need and feasibility","volume":"15","author":"R Bihariesingh-Sanchit","year":"2025","journal-title":"J Glob Health"},{"issue":"4","key":"pone.0358069.ref007","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/jca.21368","article-title":"Apheresis in developing countries around the World","volume":"30","author":"Q Eichbaum","year":"2015","journal-title":"J Clin Apher"},{"issue":"4","key":"pone.0358069.ref008","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/jca.22052","article-title":"Single center experience of therapeutic plasma exchange in a resource-constrained setting: A study of trends in scope and complications","volume":"38","author":"P Pandey","year":"2023","journal-title":"J Clin Apher"},{"issue":"4","key":"pone.0358069.ref009","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study","volume":"4","author":"PK Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"issue":"8093","key":"pone.0358069.ref010","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/S0140-6736(78)92644-2","article-title":"CONTROLLED TRIAL OF PREDNISOLONE IN ACUTE POLYNEUROPATHY","volume":"312","author":"RAC Hughes","year":"1978","journal-title":"The Lancet"},{"issue":"1","key":"pone.0358069.ref011","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0003-4975(00)01595-2","article-title":"Myasthenia gravis: recommendations for clinical research standards","volume":"70","author":"III Jaretzki A","year":"2000","journal-title":"The Annals of Thoracic Surgery"},{"issue":"2","key":"pone.0358069.ref012","first-page":"288","article-title":"Systemic lupus erythematosus disease activity index 2000","volume":"29","author":"DD Gladman","year":"2002","journal-title":"J Rheumatol"},{"issue":"5","key":"pone.0358069.ref013","doi-asserted-by":"crossref","DOI":"10.15406\/unoaj.2016.03.00096","article-title":"Outcomes of Therapeutic Plasma Exchange; One Year Single Center Experience","volume":"3","author":"T Ghonemy","year":"2016","journal-title":"UNOAJ"},{"issue":"6","key":"pone.0358069.ref014","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/1744-9987.12710","article-title":"Therapeutic Plasma Exchange Outcomes in Cairo University Hospitals: 6 Years Experience","volume":"22","author":"M Momtaz","year":"2018","journal-title":"Ther Apher Dial"},{"issue":"2","key":"pone.0358069.ref015","doi-asserted-by":"crossref","DOI":"10.1097\/PCC.0000000000001400","article-title":"Therapeutic Plasma Exchange in Critically Ill Children Requiring Intensive Care","volume":"19","author":"G Cortina","year":"2018","journal-title":"Pediatric Critical Care Medicine"},{"issue":"1","key":"pone.0358069.ref016","doi-asserted-by":"crossref","first-page":"70","DOI":"10.4266\/acc.2023.00654","article-title":"Prevalence of extracorporeal blood purification techniques in critically ill patients before and during the COVID-19 pandemic in Egypt","volume":"39","author":"AO Mohammed","year":"2024","journal-title":"Acute and Critical Care"},{"issue":"6","key":"pone.0358069.ref017","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/jca.21646","article-title":"Cost-minimization analysis in the Indian subcontinent for treating Guillain Barre Syndrome patients with therapeutic plasma exchange as compared to intravenous immunoglobulin","volume":"33","author":"A Maheshwari","year":"2018","journal-title":"J Clin Apher"},{"issue":"4","key":"pone.0358069.ref018","doi-asserted-by":"crossref","first-page":"649","DOI":"10.4103\/aam.aam_65_24","article-title":"Therapeutic Plasma Exchange in Neurological Conditions: An Observation from the Eastern Part of India","volume":"23","author":"AP Mishra","year":"2024","journal-title":"Ann Afr Med"},{"issue":"9596","key":"pone.0358069.ref019","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"E von Elm","year":"2007","journal-title":"The Lancet"},{"issue":"6","key":"pone.0358069.ref020","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/aje\/kwk052","article-title":"Relaxing the rule of ten events per variable in logistic and Cox regression","volume":"165","author":"E Vittinghoff","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"3","key":"pone.0358069.ref021","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.transci.2008.09.003","article-title":"World apheresis registry 2003\u20132007 data","volume":"39","author":"B Stegmayr","year":"2008","journal-title":"Transfusion and Apheresis Science"},{"issue":"1","key":"pone.0358069.ref022","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/jth.13882","article-title":"External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment","volume":"16","author":"A Li","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"1","key":"pone.0358069.ref023","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","volume":"80","author":"D Firth","year":"1993","journal-title":"Biometrika"},{"issue":"16","key":"pone.0358069.ref024","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1002\/sim.1047","article-title":"A solution to the problem of separation in logistic regression","volume":"21","author":"G Heinze","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"3","key":"pone.0358069.ref025","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jca.21470","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue","volume":"31","author":"J Schwartz","year":"2016","journal-title":"J Clin Apher"},{"issue":"6","key":"pone.0358069.ref026","doi-asserted-by":"crossref","first-page":"453","DOI":"10.7326\/0003-4819-131-6-199909210-00011","article-title":"Therapeutic plasma exchange: an update from the Canadian Apheresis Group","volume":"131","author":"WF Clark","year":"1999","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0358069.ref027","first-page":"7","article-title":"Complications in patients treated with plasmapheresis in the intensive care unit","volume":"45","author":"W Szczeklik","year":"2013","journal-title":"Anaesthesiol Intensive Ther"},{"issue":"5","key":"pone.0358069.ref028","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1744-9987.2005.00319.x","article-title":"Complications of therapeutic plasma exchange: experience with 4857 treatments","volume":"9","author":"N Basic-Jukic","year":"2005","journal-title":"Ther Apher Dial"},{"issue":"4","key":"pone.0358069.ref029","article-title":"Plasma exchange for myasthenia gravis","volume":"2002","author":"P Gajdos","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"pone.0358069.ref030","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001798.pub3","article-title":"Plasma exchange for Guillain-Barr\u00e9 syndrome","volume":"2017","author":"S Chevret","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"pone.0358069.ref031","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrrheum.2014.103","article-title":"Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease","volume":"10","author":"JC Jennette","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"9843","key":"pone.0358069.ref032","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/S0140-6736(11)61454-2","article-title":"Acute kidney injury","volume":"380","author":"R Bellomo","year":"2012","journal-title":"The Lancet"},{"issue":"6","key":"pone.0358069.ref033","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/RHU.0000000000000291","article-title":"Systematic Review of Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus: Focus on Outcome and Therapy","volume":"21","author":"C Ednalino","year":"2015","journal-title":"J Clin Rheumatol"},{"issue":"6","key":"pone.0358069.ref034","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/art.39562","article-title":"Diffuse Alveolar Hemorrhage Secondary to Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Predictors of Respiratory Failure and Clinical Outcomes","volume":"68","author":"R Cartin-Ceba","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"pone.0358069.ref035","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"M Scully","year":"2012","journal-title":"Br J Haematol"},{"issue":"5","key":"pone.0358069.ref036","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.3390\/jcm9051597","article-title":"Plasma Exchange or Immunoadsorption in Demyelinating Diseases: A Meta-Analysis","volume":"9","author":"M Lipphardt","year":"2020","journal-title":"J Clin Med"},{"issue":"8","key":"pone.0358069.ref037","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1007\/s00134-015-3934-7","article-title":"Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study","volume":"41","author":"EAJ Hoste","year":"2015","journal-title":"Intensive Care Med"},{"issue":"1","key":"pone.0358069.ref038","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2141.2004.04972.x","article-title":"Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant","volume":"126","author":"DF O\u2019Shaughnessy","year":"2004","journal-title":"Br J Haematol"},{"issue":"7","key":"pone.0358069.ref039","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(07)70130-8","article-title":"A clinical prognostic scoring system for Guillain-Barr\u00e9 syndrome","volume":"6","author":"R van Koningsveld","year":"2007","journal-title":"Lancet Neurol"},{"issue":"11","key":"pone.0358069.ref040","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1212\/WNL.0b013e3182104407","article-title":"Early recognition of poor prognosis in Guillain-Barre syndrome","volume":"76","author":"C Walgaard","year":"2011","journal-title":"Neurology"},{"issue":"8","key":"pone.0358069.ref041","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1212\/WNL.35.8.1096","article-title":"Plasmapheresis and acute Guillain\u2010Barre syndrome","volume":"35","year":"1985","journal-title":"Neurology"},{"issue":"7","key":"pone.0358069.ref042","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/jnnp-2011-301882","article-title":"Outcome and its predictors in Guillain-Barre syndrome","volume":"83","author":"YA Rajabally","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"pone.0358069.ref043","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/trf.14479","article-title":"Vascular access for therapeutic plasma exchange","author":"TS Ipe","year":"2018","journal-title":"Transfusion"},{"issue":"6","key":"pone.0358069.ref044","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jinf.2019.09.014","article-title":"Safety and effectiveness of apheresis in the treatment of infectious diseases: A systematic review","volume":"79","author":"A Odedra","year":"2019","journal-title":"J Infect"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0358069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:41:23Z","timestamp":1789148483000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0358069"}},"subtitle":[],"editor":[{"given":"Awais","family":"ALi","sequence":"first","affiliation":[{"name":"Abdul Wali Khan University Mardan","place":["PAKISTAN"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":44,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,11]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0358069","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}